0 CHECKOUT

Hepatic Encephalopathy - Pipeline Review, H1 2015

  • ID: 3112117
  • January 2015
  • 49 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • Alfa Wassermann S.p.A
  • Ocera Therapeutics, Inc.
  • Umecrine Cognition AB
  • MORE

Hepatic Encephalopathy - Pipeline Review, H1 2015

Summary

This, ‘Hepatic Encephalopathy - Pipeline Review, H1 2015’, provides an overview of the Hepatic Encephalopathy’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Hepatic Encephalopathy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hepatic Encephalopathy and special features on late-stage and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic READ MORE >

Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Alfa Wassermann S.p.A
  • Ocera Therapeutics, Inc.
  • Umecrine Cognition AB
  • MORE

List of Tables
List of Figures
Introduction
REPORT COVERAGE
Hepatic Encephalopathy Overview
Therapeutics Development
Pipeline Products for Hepatic Encephalopathy - Overview
Pipeline Products for Hepatic Encephalopathy - Comparative Analysis
Hepatic Encephalopathy - Therapeutics under Development by Companies
Hepatic Encephalopathy - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Hepatic Encephalopathy - Products under Development by Companies
Hepatic Encephalopathy - Companies Involved in Therapeutics Development
Alfa Wassermann S.p.A
Hyperion Therapeutics, Inc.
Ocera Therapeutics, Inc.
Umecrine Cognition AB
Hepatic Encephalopathy - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
CVXL-0060 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
glycerol phenylbutyrate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ornithine phenylacetate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
rifaximin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
THDP-17 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Hepatic Encephalopathy - Recent Pipeline Updates
Hepatic Encephalopathy - Dormant Projects
Hepatic Encephalopathy - Product Development Milestones
Featured News & Press Releases
Sep 18, 2014: Salix Secures Additional Intellectual Property Relating to Rifaximin
Sep 12, 2014: Lupin and Salix Announce Exclusive Distribution Agreement for Zaxine in Canada
Feb 25, 2014: Hyperion Therapeutics Announces the Publication of Phase 2 Results of Glycerol Phenylbutyrate for the Treatment of Hepatic Encephalopathy in Hepatology
Feb 14, 2014: Luxembourg National Health Fund Approves Reimbursement Of Xifaxan 550
Feb 04, 2014: Salix Pharmaceuticals Announces Issuance Of U. S. Patent For Rifaximin
Jan 08, 2014: Ocera Therapeutics Announces Enrollment of the First Patient in a Phase IIb Study for Treatment of Acute Hepatic Encephalopathy
Nov 01, 2013: Salix Pharmaceuticals Outlines Data Presentations at American Association for the Study of Liver Diseases Annual Meeting
Sep 09, 2013: Scottish Medicines Consortium Accepts TARGAXAN 550
May 24, 2013: Norgine Announces PBAC Approval For Xifaxan 550mg In Prevention Of Recurrence Of Hepatic Encephalopathy
May 17, 2013: Salix Pharma To Present Data On Rifaximin At Digestive Disease Week 2013
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Hepatic Encephalopathy, H1 2015
Number of Products under Development for Hepatic Encephalopathy - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Comparative Analysis by Late Stage Development, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Development, H1 2015
Products under Development by Companies, H1 2015
Hepatic Encephalopathy - Pipeline by Alfa Wassermann S.p.A, H1 2015
Hepatic Encephalopathy - Pipeline by Hyperion Therapeutics, Inc., H1 2015
Hepatic Encephalopathy - Pipeline by Ocera Therapeutics, Inc., H1 2015
Hepatic Encephalopathy - Pipeline by Umecrine Cognition AB, H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Stage and Target, H1 2015
Number of Products by Stage and Mechanism of Action, H1 2015
Number of Products by Stage and Route of Administration, H1 2015
Number of Products by Stage and Molecule Type, H1 2015
Hepatic Encephalopathy Therapeutics - Recent Pipeline Updates, H1 2015
Hepatic Encephalopathy - Dormant Projects, H1 2015

List of Figures
Number of Products under Development for Hepatic Encephalopathy, H1 2015
Number of Products under Development for Hepatic Encephalopathy - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Comparative Analysis by Early Stage Products, H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Top 10 Targets, H1 2015
Number of Products by Stage and Top 10 Targets, H1 2015
Number of Products by Top 10 Mechanism of Actions, H1 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015
Number of Products by Top 10 Routes of Administration, H1 2015
Number of Products by Stage and Top 10 Routes of Administration, H1 2015
Number of Products by Stage and Top 10 Molecule Types, H1 2015

Note: Product cover images may vary from those shown
3 of 4

Alfa Wassermann S.p.A
Hyperion Therapeutics, Inc.
Ocera Therapeutics, Inc.
Umecrine Cognition AB

Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown

PURCHASING OPTIONS

HAVE A QUESTION?

EMAIL US VIEW FAQs

RELATED PRODUCTS from Db

Our Clients

  • Shire PLC.
  • GlaxoSmithKline PLC
  • Astrazeneca PLC
  • Roche Diagnostics Ltd.
  • H. Lundbeck A/S
  • Electrical Geodesics, Inc.